Point72 Asia (Singapore) Pte. Ltd. Immuneering Corp Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $480 Billion
- Q2 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Immuneering Corp stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 34,609 shares of IMRX stock, worth $80,292. This represents 0.01% of its overall portfolio holdings.
Number of Shares
34,609Holding current value
$80,292% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding IMRX
# of Institutions
60Shares Held
9.65MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.88MShares$4.37 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.07MShares$2.48 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny953KShares$2.21 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD859KShares$1.99 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY742KShares$1.72 Million0.0% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $61.2M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...